Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 97, showing 5 Applications out of 482 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/24/06/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
 
View

12.

ECCT/24/06/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Jesse Gitaka
Site(s) in Kenya
1. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. KEMRI-Mtwapa Clinical Annex (Kilifi county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

13.

ECCT/24/05/06   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county)
 
View

14.

ECCT/24/05/05   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Kariuki Simon Kariuki
2. Patricia Odero Ojwang
Site(s) in Kenya
1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county)
 
View

15.

ECCT/24/05/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county)
 
View